GENVOYA (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate) Patent Expiration, LOE Window & CMS Spending
GENVOYA (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate) by Gilead Sciences: FDA Orange Book core substance LOE 2033-04-06, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N207561 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2033-04-06 |
| Last Listed Patent or Exclusivity Date | 2033-04-06 |
| Orange Book Patents (*PED Extensions) | 18 patents (9 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.